HRP20201975T1 - Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba - Google Patents
Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba Download PDFInfo
- Publication number
- HRP20201975T1 HRP20201975T1 HRP20201975TT HRP20201975T HRP20201975T1 HR P20201975 T1 HRP20201975 T1 HR P20201975T1 HR P20201975T T HRP20201975T T HR P20201975TT HR P20201975 T HRP20201975 T HR P20201975T HR P20201975 T1 HRP20201975 T1 HR P20201975T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title claims 3
- 241000700605 Viruses Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 241000712431 Influenza A virus Species 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (11)
1. Izolirano protutijelo, ili njegov ulomak koji veže antigen, koje neutralizira infekciju podskupa grupe 1 i podskupa grupe 2 virusa influence A i obuhvaća: (i) sekvence CDR1, CDR2 i CDR3 teškog lanca kao što je navedeno u SEQ ID NOs: 1, 41 i 43, redom, ili kao što je navedeno u SEQ ID NOs: 1, 41 i 42, redom; i (ii) sekvence CDR1, CDR2, i CDR3 lakog lanca kako je navedeno u SEQ ID NOs: 4, 5 i 6, redom, ili kao što je navedeno u SEQ ID NOs: 44, 5 i 6, redom,
pri čemu se navedeno protutijelo, ili njegov ulomak koji veže antigen, proizvodi u transfektiranim stanicama u titrima najmanje 3 puta višim od titra u kojem se proizvodi FI6 varijanta 2.
2. Protutijelo prema zahtjevu 1, ili njegov ulomak koji veže antigen, naznačeno time što sadrži varijabilnu regiju teškog lanca koja ima najmanje 80% identičnosti sekvence sa sekvencom aminokiseline kao što je navedeno u SEQ ID NOs: 59 ili 55; i varijabilnu regiju lakog lanca koja ima najmanje 80% identičnosti sekvence sa sekvencom aminokiseline kao što je navedeno u SEQ ID NOs: 57 ili 61.
3. Izolirano protutijelo, ili njegov ulomak koji veže antigen, naznačeno time što sadrži varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 59 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 57; ili varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 59 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 61; ili varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 55 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 57; ili varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 55 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 61, i pri čemu protutijelo neutralizira podskup grupe 1 i podskup grupe 2 virusa influence A.
4. Protutijelo prema bilo kojem od prethodnih zahtjeva, ili njegov ulomak koji veže antigen, naznačeno time što je protutijelo ljudsko protutijelo, monoklonsko protutijelo, pročišćeno protutijelo, jednolančano protutijelo, Fab, Fab', F(ab')2, Fv ili scFv.
5. Protutijelo prema bilo kojem od prethodnih zahtjeva, ili njegov ulomak koji veže antigen, naznačeno time što je za uporabu u liječenju infekcije virusom influence A.
6. Molekula nukleinske kiseline naznačena time što sadrži polinukleotid koji kodira protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od prethodnih zahtjeva.
7. Vektor naznačen time što sadrži molekulu nukleinske kiseline iz zahtjeva 6.
8. Stanica naznačena time što eksprimira protutijelo prema bilo kojem od patentnih zahtjeva 1 - 4, ili njegov ulomak koji veže antigen; ili sadrži vektor prema zahtjevu 7.
9. Farmaceutski pripravak naznačen time što sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 - 4, ili njegov ulomak koji veže antigen, nukleinsku kiselinu prema zahtjevu 6, vektor prema zahtjevu 7, ili stanicu prema zahtjevu 8, i farmaceutski prihvatljivo sredstvo za razrjeđivanje ili nosač.
10. Protutijelo prema bilo kojem od patentnih zahtjeva 1 -4, ili njegov ulomak koji veže antigen, nukleinsku kiselinu prema zahtjevu 6, vektor prema zahtjevu 7, stanicu prema zahtjevu 8, ili farmaceutski pripravak prema zahtjevu 9 (i) za uporabu kao lijek za liječenje infekcije virusom influence, (ii) u cjepivu, ili (iii) u dijagnostici infekcije virusom influence A.
11. Uporaba protutijela prema bilo kojem od zahtjeva 1 -4, ili njegovog ulomka koji veže antigen, naznačena time što je za praćenje kvalitete cjepiva protiv virusa influence A provjerom da li antigen navedenog cjepiva sadrži specifični epitop u ispravnoj konformaciji.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2011/002329 WO2013011347A1 (en) | 2011-07-18 | 2011-07-18 | Neutralizing anti-influenza a virus antibodies and uses thereof |
EP18180926.0A EP3418300B1 (en) | 2011-07-18 | 2011-07-18 | Neutralizing anti-influenza a virus antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201975T1 true HRP20201975T1 (hr) | 2021-02-05 |
Family
ID=44993618
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190714TT HRP20190714T1 (hr) | 2011-07-18 | 2019-04-16 | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba |
HRP20201975TT HRP20201975T1 (hr) | 2011-07-18 | 2020-12-10 | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190714TT HRP20190714T1 (hr) | 2011-07-18 | 2019-04-16 | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba |
Country Status (15)
Country | Link |
---|---|
US (3) | US9587010B2 (hr) |
EP (3) | EP3812397A1 (hr) |
JP (1) | JP6035332B2 (hr) |
CN (1) | CN103717617B (hr) |
AU (1) | AU2011373387B2 (hr) |
CA (1) | CA2841551C (hr) |
DK (2) | DK3418300T3 (hr) |
ES (2) | ES2732552T3 (hr) |
HR (2) | HRP20190714T1 (hr) |
HU (2) | HUE044089T2 (hr) |
LT (2) | LT2734545T (hr) |
MX (1) | MX352338B (hr) |
PL (2) | PL3418300T3 (hr) |
SI (2) | SI3418300T1 (hr) |
WO (1) | WO2013011347A1 (hr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
JP5947289B2 (ja) | 2010-05-10 | 2016-07-06 | アカデミア シニカAcademia Sinica | 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定 |
PL3418300T3 (pl) | 2011-07-18 | 2021-05-04 | Institute For Research In Biomedicine | Neutralizujące przeciwciała przeciwko wirusowi grypy A i ich zastosowania |
CN107417789A (zh) * | 2011-07-18 | 2017-12-01 | 生物医学学会 | 中和抗甲型流感病毒抗体及其用途 |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
WO2014031762A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
TWI657095B (zh) | 2012-11-13 | 2019-04-21 | 美商建南德克公司 | 抗血球凝集素抗體及使用方法 |
KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
EP3041484B1 (en) | 2013-09-06 | 2021-03-03 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
AU2014329609B2 (en) * | 2013-10-02 | 2019-09-12 | Humabs Biomed Sa | Neutralizing anti-influenza A antibodies and uses thereof |
AU2015206370A1 (en) | 2014-01-16 | 2016-07-07 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2940196C (en) * | 2014-03-19 | 2023-03-07 | Wayne Marasco | Immunogenetic restriction on elicitation of antibodies |
TWI687428B (zh) | 2014-03-27 | 2020-03-11 | 中央研究院 | 反應性標記化合物及其用途 |
US10344058B2 (en) | 2014-05-01 | 2019-07-09 | Indian Institute Of Science | Polypeptides for generating anti-influenza antibodies and uses thereof |
KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
US10005847B2 (en) | 2014-05-27 | 2018-06-26 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR102576850B1 (ko) | 2014-05-27 | 2023-09-11 | 아카데미아 시니카 | 박테로이드 기원의 푸코시다제 및 이의 사용 방법 |
CA2950433A1 (en) | 2014-05-28 | 2015-12-03 | Academia Sinica | Anti-tnf-alpha glycoantibodies and uses thereof |
AU2015289805B2 (en) * | 2014-07-15 | 2020-06-25 | Humabs Biomed Sa | Neutralizing anti-influenza B antibodies and uses thereof |
JP6899321B2 (ja) | 2014-09-08 | 2021-07-07 | アカデミア シニカAcademia Sinica | 糖脂質を使用するヒトiNKT細胞活性化 |
TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
JP6772157B2 (ja) * | 2015-02-05 | 2020-10-21 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | インフルエンザヘマグルチニンに対する結合分子及びその使用 |
GB201502137D0 (en) | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
WO2016164835A1 (en) * | 2015-04-08 | 2016-10-13 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
CN107667114B (zh) | 2015-06-01 | 2021-07-02 | 免疫医疗有限责任公司 | 中和抗流感结合分子及其用途 |
EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
IL304940A (en) * | 2016-01-13 | 2023-10-01 | Medimmune Llc | A method for treating type A influenza |
CA3015347A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
TW201808978A (zh) | 2016-03-08 | 2018-03-16 | 中央研究院 | N-聚醣及其陣列之模組化合成方法 |
WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
AU2017261305A1 (en) * | 2016-05-05 | 2018-12-20 | Inovio Pharmaceuticals, Inc. | DNA monoclonal antibodies targeting influenza virus |
CN109963868B (zh) | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | 抗体、结合片段及使用方法 |
WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
CN107868121B (zh) * | 2016-09-28 | 2021-03-16 | 中国医学科学院病原生物学研究所 | H3亚型流感病毒血凝素特异性保守表位、其抗体及其应用 |
EP3574008B1 (en) | 2017-01-27 | 2023-11-08 | National Research Council of Canada | Hemagglutinin-specific antibodies and uses thereof |
WO2020198329A1 (en) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
WO2021055798A1 (en) * | 2019-09-19 | 2021-03-25 | Duke University | Influenza neutralizing antibodies and their uses |
WO2021055679A1 (en) * | 2019-09-20 | 2021-03-25 | Academia Sinica | Chimeric hemagglutinin protein and a vaccine composition comprising the same |
IL293804A (en) | 2019-12-11 | 2022-08-01 | Visterra Inc | Anti-hemagglutinin (ha) antibody molecules, preparations containing them and their uses |
WO2023081471A1 (en) * | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
CN117430664B (zh) * | 2023-10-24 | 2024-04-09 | 暨南大学附属第六医院(东莞市东部中心医院) | 一种甲型流感病毒t细胞抗原表位肽及其应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB819376A (en) | 1956-10-20 | 1959-09-02 | Colne Switchgear K & W Ltd | Improvements in electro-magnetic overload units for electrical apparatus |
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
WO1998057993A1 (en) | 1997-06-19 | 1998-12-23 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
JP4656478B2 (ja) | 2000-02-22 | 2011-03-23 | 株式会社医学生物学研究所 | 抗体ライブラリー |
US7175999B2 (en) | 2002-07-11 | 2007-02-13 | The General Hospital Corporation | Polynucleotide and polypeptide fat metabolism regulators and uses thereof |
WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
EP1666059A4 (en) | 2003-08-11 | 2008-08-27 | Univ Osaka Res Found | NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
AU2007249160B2 (en) | 2006-05-15 | 2013-09-12 | I2 Pharmaceuticals, Inc. | Neutralizing antibodies to influenza viruses |
CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
PL2059532T3 (pl) | 2006-09-07 | 2013-05-31 | Crucell Holland Bv | Ludzkie cząsteczki wiążące zdolne do neutralizowania wirusa grypy H5N1 i ich zastosowania |
ES2859825T3 (es) | 2006-10-02 | 2021-10-04 | Regeneron Pharma | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
WO2008066691A2 (en) | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7 and antibodies that bind thereto |
EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
JP5346820B2 (ja) | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | H5n1亜型a型インフルエンザウィルスに対する抗体 |
KR101956910B1 (ko) | 2008-01-21 | 2019-03-12 | 메디카고 인코포레이티드 | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs) |
ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
JP5607620B2 (ja) * | 2008-07-25 | 2014-10-15 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | 抗a型インフルエンザウイルス中和抗体およびその使用 |
CA2740138C (en) | 2008-10-22 | 2017-01-10 | Institute For Research In Biomedicine | Methods for producing antibodies from plasma cells |
WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
US10272148B2 (en) | 2009-06-24 | 2019-04-30 | Medicago Inc. | Chimeric influenza virus-like particles comprising hemagglutinin |
PL3418300T3 (pl) | 2011-07-18 | 2021-05-04 | Institute For Research In Biomedicine | Neutralizujące przeciwciała przeciwko wirusowi grypy A i ich zastosowania |
-
2011
- 2011-07-18 PL PL18180926T patent/PL3418300T3/pl unknown
- 2011-07-18 DK DK18180926.0T patent/DK3418300T3/da active
- 2011-07-18 LT LTEP11784765.7T patent/LT2734545T/lt unknown
- 2011-07-18 SI SI201131938T patent/SI3418300T1/sl unknown
- 2011-07-18 SI SI201131700T patent/SI2734545T1/sl unknown
- 2011-07-18 WO PCT/IB2011/002329 patent/WO2013011347A1/en active Application Filing
- 2011-07-18 EP EP20200200.2A patent/EP3812397A1/en active Pending
- 2011-07-18 CN CN201180072356.0A patent/CN103717617B/zh active Active
- 2011-07-18 HU HUE11784765A patent/HUE044089T2/hu unknown
- 2011-07-18 EP EP11784765.7A patent/EP2734545B1/en active Active
- 2011-07-18 AU AU2011373387A patent/AU2011373387B2/en active Active
- 2011-07-18 ES ES11784765T patent/ES2732552T3/es active Active
- 2011-07-18 HU HUE18180926A patent/HUE051756T2/hu unknown
- 2011-07-18 EP EP18180926.0A patent/EP3418300B1/en active Active
- 2011-07-18 JP JP2014520738A patent/JP6035332B2/ja active Active
- 2011-07-18 MX MX2014000749A patent/MX352338B/es active IP Right Grant
- 2011-07-18 US US14/233,719 patent/US9587010B2/en active Active
- 2011-07-18 PL PL11784765T patent/PL2734545T3/pl unknown
- 2011-07-18 DK DK11784765.7T patent/DK2734545T3/en active
- 2011-07-18 LT LTEP18180926.0T patent/LT3418300T/lt unknown
- 2011-07-18 CA CA2841551A patent/CA2841551C/en active Active
- 2011-07-18 ES ES18180926T patent/ES2841899T3/es active Active
-
2017
- 2017-01-20 US US15/411,677 patent/US20170204167A1/en not_active Abandoned
-
2018
- 2018-11-01 US US16/178,497 patent/US10815294B2/en active Active
-
2019
- 2019-04-16 HR HRP20190714TT patent/HRP20190714T1/hr unknown
-
2020
- 2020-12-10 HR HRP20201975TT patent/HRP20201975T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
HRP20201505T1 (hr) | Široko neutralizirajuća anti-hiv protutijela | |
HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
HRP20210096T1 (hr) | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
HRP20231196T1 (hr) | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba | |
RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
JP2012010714A5 (hr) | ||
JP2011528902A5 (hr) | ||
RU2668802C2 (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
JP2014511179A5 (hr) | ||
HRP20200607T1 (hr) | Rsv-specifična protutijela i njihovi funkcionalni dijelovi | |
RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
JP2014519334A5 (hr) | ||
RU2013102073A (ru) | Антитела, подходящие для пассивной иммунизации против гриппа | |
JP2016530223A5 (hr) | ||
JP2013531993A5 (hr) | ||
US10400031B2 (en) | Identification of antibodies specific for lyssaviruses and methods of their use |